Licensing status

Publication and contact information


Pancreatic cancer

ADAM10; amyloid precursor protein (APP)

Cell culture studies suggest inhibiting ADAM10 or secreted APP could increase the efficacy of Gemzar gemcitabine in pancreatic cancer. In human pancreatic cancer cell lines, pharmacological inhibition of ADAM10, which is frequently overexpressed in pancreatic cancer, was shown to prevent the generation of secreted APP. In human pancreatic cancer cell lines, small interfering RNA against ADAM10 increased Gemzar sensitivity compared with control siRNA. Next steps include evaluating the safety and additive or synergistic effects of the combination in mouse pancreatic cancer models.
Eli Lilly and Co. markets the nucleoside analog Gemzar to treat pancreatic and other cancers.

SciBX 6(39); doi:10.1038/scibx.2013.1094
Published online Oct. 10, 2013

Unpatented; licensing status not applicable

Woods, N.K. & Padmanabhan, J.
J. Biol. Chem.; published online
Sept. 10, 2013;
Contact: Jaya Padmanabhan, University of South Florida, Tampa, Fla.